NHT
VRTX icon

New Hampshire Trust’s Vertex Pharmaceuticals VRTX Stock Holding History

New Hampshire Trust’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-100
Closed -$31.5K – 342
2023
Q1 		$31.5K Hold
100
– – 0.01% 274
2022
Q4 		$28.9K Buy
+100
New +$30.5K 0.01% 283

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

New Hampshire Trust's VRTX Position: Q2 2023 in Review

New Hampshire Trust sold out of Vertex Pharmaceuticals (VRTX) in Q2 2023, closing a stake of 100 shares — an estimated $31.5K sold.

New Hampshire Trust first reported a position in VRTX in Q4 2022 and held it in 2 quarters. The position peaked at $31.5K in Q1 2023. 1,285 funds tracked by Wall St. Rank hold VRTX as of Q2 2023.

  • New Hampshire Trust reported no remaining Vertex Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • New Hampshire Trust sold 100 Vertex Pharmaceuticals shares in Q2 2023, an estimated $31.5K.
  • New Hampshire Trust first reported a position in Vertex Pharmaceuticals in Q4 2022 and held it in 2 quarters.
  • New Hampshire Trust's Vertex Pharmaceuticals position peaked at $31.5K in Q1 2023.
  • 1,285 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2023.

Based on New Hampshire Trust's 13F filing for Q2 2023, filed 11 Jul 2023.